NCT07743476

Brief Summary

To create a registry for people who are undergoing or previously underwent radiotherapy for hematologic or related disorders.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
145mo left

Started Jan 2027

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 30, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 4, 2026

Completed
6 months until next milestone

Study Start

First participant enrolled

January 23, 2027

Expected
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2036

2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2038

Last Updated

August 4, 2026

Status Verified

July 1, 2026

Enrollment Period

9.9 years

First QC Date

July 30, 2026

Last Update Submit

July 30, 2026

Conditions

Marrow ReserveClinical OutcomesHematologicRadiotherapyQuantitative Marrow Imaging

Outcome Measures

Primary Outcomes (1)

  • Safety and adverse events (AEs).

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Through study completion; an average of 1 year.

Interventions

data collectionOTHER

The study will collect clinical, imaging, laboratory, treatment, and outcome data from the electronic medical record, radiation treatment planning systems, imaging archives, and other institutional clinical databases

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

UT MD Anderson Cancer Center

You may qualify if:

  • Undergoing or previously underwent radiotherapy at The University of Texas MD Anderson Cancer Center for hematologic or related disorders.
  • Available clinical, imaging, laboratory, treatment, and/or outcome data relevant to study objectives.
  • Ability to provide informed consent for prospective participation, when applicable.

You may not qualify if:

  • Participants meeting any of the following criteria will be excluded:
  • Inability to provide informed consent, or when applicable, the absence of a legally authorized representative able to provide consent for prospective participation.
  • Insufficient clinical information available to support study objectives.
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Interventions

Data Collection

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Omran Saifi, MD

    UT MD Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Omran Saifi, MD

CONTACT

832-829-0337OSaifi@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2026

First Posted

August 4, 2026

Study Start (Estimated)

January 23, 2027

Primary Completion (Estimated)

December 31, 2036

Study Completion (Estimated)

December 31, 2038

Last Updated

August 4, 2026

Record last verified: 2026-07

Locations

US(1)